Summary
You may be eligible for this study if you have multiple myeloma that has relapsed following first line therapy, and require treatment with daratumumab, bortezomib and dexamethasone.
Daratumumab, bortezomib and dexamethasone are the current standard of care treatment. Daratumumab is currently administered in the hospital. Bortezomib can be administered at home if your hospital has programs in place for this to happen. Dexamethasone is a tablet that you can take in your own home.
The Dara@home trial is to assess the feasibility of implementing a program to allow patients to self-administer daratumumab at home. In addition to standard tests used to treat and monitor your myeloma, this study will have additional questionnaires for you to report your experience with myeloma treatment. There is also an additional blood test to assess the level daratumumab in your blood to ensure that the treatment is working.
It is hoped that findings from this study will give insight on the possibility of having daratumumab to be self-administered at home, which can reduce your visits to the hospital.